Live prices from 6 SA suppliers, from R299.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 3 prices for HGH. Cheapest: R1,089.00. Average: R1,192.67.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
Peptide Pen
Best
HGH 10mg |
R1,089.00 | R108.90/mg | In Stock | R250.00 |
—
|
— | ||
|
HGH 10mg |
R1,130.00 | R113.00/mg | In Stock | R160.00 |
—
|
— | ||
|
HGH 10mg |
R1,359.00 | R135.90/mg | In Stock | R250.00 |
—
|
— |
More ways to compare HGH
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Human Growth Hormone | Somatropin
Human Growth Hormone (HGH/Somatropin) is a 191-amino acid polypeptide hormone FDA-approved for pediatric and adult growth hormone deficiency, HIV-associated wasting, and other conditions. It provides both direct and indirect (IGF-1 mediated) anabolic effects.
Binds to GH receptors on target tissues, triggering JAK2-STAT5 signaling pathway. Direct effects include lipolysis, protein synthesis, and metabolic regulation. Indirect effects via IGF-1 promote growth and anabolism. Half-life ~3 hours subcutaneously.
FDA-approved for idiopathic and organic causes, Turner syndrome, Prader-Willi syndrome, SGA, Noonan syndrome, SHOX deficiency.
FDA-approved for childhood-onset or adult-onset causes (pituitary tumors, surgery, radiation, trauma).
FDA-approved to increase lean body mass and body weight in cachexia.
Significant fat loss especially abdominal/visceral fat over 1-3 months.
Increased muscle mass and improved body composition.
Enhanced exercise recovery and tissue healing.
Improved skin elasticity, texture, and hair/nail growth.
Improved energy, sleep, and quality of life.
Subcutaneous injection is the only effective route. Morning fasted injection maximizes fat-burning potential; evening mimics natural nocturnal GH pulse.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Medical GHD (Starting) | 0.15-0.3mg/day (0.5-1 IU) | Once daily | SubQ |
| Medical GHD (Maintenance) | 0.4-0.8mg/day (1.2-2.4 IU) | Once daily | SubQ |
| Anti-Aging/Wellness | 1-2 IU/day (0.33-0.67mg) | Once daily | SubQ |
| Body Recomposition | 2-4 IU/day (0.67-1.33mg) | Once or twice daily | SubQ |
| Performance (Higher Risk) | 4-8 IU/day (1.33-2.67mg) | Split twice daily | SubQ |
HGH decreases insulin sensitivity; may require increased insulin doses in diabetics.
Synergistic but caution: enhanced effects with increased hypoglycemia and side effect risk.
Increases T4 to T3 conversion; unmasks hypothyroidism in 36-47% of patients.
GHRH analog can enhance effects though may be redundant with exogenous HGH.
Ghrelin mimetic works via different pathway.
Enhances natural pulsatile release.
Can unmask cortisol deficiency; replacement should precede HGH.
Commonly combined in hormone replacement therapy.
May manage insulin resistance; may reduce IGF-1 levels.
GLP-1 agonists help manage insulin resistance during HGH therapy.
Improved sleep quality, increased energy, possible water retention and joint stiffness
Enhanced exercise recovery, skin improvement, possible carpal tunnel symptoms
Noticeable fat loss (especially abdominal), improved skin elasticity and texture
Continued fat loss, lean mass improvements, hair/nail growth, reduced recovery time
Significant body composition changes, improved bone density, sustained energy/well-being
Maintained benefits; effects diminish weeks-months after discontinuation
FDA
Sogroya and Skytrofa FDA-approved for improved once-weekly dosing convenience.
15,809 patients, mean 5.3 years follow-up. Largest long-term safety study showing de novo cancer incidence comparable to general population (SIR 0.92).
Systematic review demonstrating improvements in body composition, muscle strength, quality of life, bone mass/density, and lipoprotein patterns.
Demonstrated positive effects on cardiovascular surrogate markers and bone metabolism.
GH replacement unmasks central hypothyroidism in 36-47% of apparently euthyroid patients.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.